

WHEREAS, companies in the biopharmaceutical industry and members of America's building trades unions have a 15-year history of partnership, formally united through the Pharmaceutical Industry Labor-Management Association (PILMA); and,

WHEREAS, the biopharmaceutical industry is a world-leader in innovation, which leads to new discoveries that cure disease, save lives and contributes to U.S. economic growth; and,

WHEREAS, on average a new medicine that goes to market costs \$2.6 billion and takes 10 years to go through the entire R&D process; and,

WHEREAS, through this investment in future medical innovation, the biopharmaceutical sector is responsible for the largest share of business R&D in the U.S. economy and supports more than 4.7 million American jobs; and,

WHEREAS, when COVID-19 spread throughout the world causing unprecedented illness and loss of life, America's biopharmaceutical companies developed multiple COVID-19 vaccines and treatments in record time, and continue to innovate for the health of all Americans and the world; and,

WHEREAS, the biopharmaceutical industry responded to the worldwide COVID-19 pandemic with unprecedented effort to develop vaccines and therapies; and,

WHEREAS, North America's Building Trades Unions stood at the front lines of the pandemic with essential workers, donating supplies and working safely to stand up facilities in the industry to research and develop these medicines; and,

WHEREAS, a recent PILMA study shows that between 2012 - 2017, there were 249 major biopharmaceutical construction projects in 11 key states, representing \$14.3 billion in infrastructure investment, requiring at least 15.6 million union labor hours; and,

WHEREAS, the U.S. biopharmaceutical industry requires a solid and predictable regulatory environment in order to invest in the infrastructure built by America's building trades where medical research, development and manufacturing takes place; therefore,

BE IT RESOLVED, that PILMA supports policies and a regulatory environment that allows biopharmaceutical innovation to thrive for the health of all Americans and the world; and,

BE IT FURTHER RESOLVED, that policies fostering the biopharmaceutical industry's ability to research and develop medicines supports American jobs including good paying union construction jobs that keep workers in the middle-class; and,

BE IT FURTHER RESOLVED, that the unions and companies of PILMA believe that policies such as price controls and foreign reference pricing will inhibit further discovery and treatments to fight future pandemics; and,

BE IT FURTHER RESOLVED, that PILMA will call on federal, state and local policymakers to uphold the innovation ecosystem that has aided America's biopharmaceutical companies in developing a COVID-19 vaccine in record time and will be relied upon for future treatments and cures.